Combination of pet imaging with viral vectors for identification of cancer metastases

Advanced Drug Delivery Reviews

Volumn 64, Issue 8, 2012, Pages 749-755

  Brader, Peter ^a   Wong, Richard J ^b   Horowitz, Gilad ^c   Gil, Ziv ^c  

^a UNIV KLIN FÜR RADIODIAGNOSTIK   (Austria)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Gene therapy; Lymph node metastases; Melanoma; Molecular imaging; Oncolytic virus; Positron emission tomography; Reporter genes

Indexed keywords

ANIMAL MODELS OF CANCER; CANCER CELLS; CANCER METASTASIS; CANCER PATIENTS; CONVENTIONAL IMAGING; HERPES SIMPLEX; LYMPH NODE METASTASIS; MELANOMA; NEOPLASTIC DISEASE; NON-INVASIVE IMAGING; NONVIRAL VECTORS; NORMAL TISSUE; OCCULT METASTASIS; PATIENT CARE; PET IMAGING; POTENTIAL BENEFITS; REPORTER GENE; REPORTER SYSTEMS; SOLID TUMORS; TARGET CELLS; THYMIDINE KINASE; VIRAL VECTORS; VIRUS-1;

DIAGNOSIS; DISEASES; ENZYMES; GENE THERAPY; GENES; IMAGING TECHNIQUES; MOLECULAR IMAGING; PATIENT TREATMENT; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; TISSUE; VECTORS; VIRUSES;

PATHOLOGY;

(3 IODOBENZYL)GUANIDINE I 131; 5 ETHYL 2' FLUOROURACIL ARABINOSIDE F 18; 9 (4 FLUORO 3 HYDROXYMETHYLBUTYL)GUANINE F 18; ADENOVIRUS VECTOR; FIALURIDINE I 131; FLUORODEOXYGLUCOSE F 18; GANCICLOVIR; NV 1023; ONCOLYTIC HERPES VIRUS; TRACER; UNCLASSIFIED DRUG; VIRUS VECTOR;

BETA GALACTOSIDASE GENE; BONE METASTASIS; BREAST CANCER; CANCER INFILTRATION; CANCER INVASION; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN; INGUINAL LYMPH NODE; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MICROMETASTASIS; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; PERINEURIUM; POPLITEAL LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SENSITIVITY AND SPECIFICITY; THYMIDINE KINASE GENE; UNSPECIFIED SIDE EFFECT;

ANIMALS; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASM MICROMETASTASIS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84860638334     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.04.007     Document Type: Review

References (82)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
2. Tobler N.E., Detmar M. Tumor and lymph node lymphangiogenesis-impact on cancer metastasis. J. Leukoc. Biol. 2006, 80:691-696.
3. Garbe C., Hauschild A., Volkenandt M., Schadendorf D., Stolz W., Reinhold U., Kortmann R.D., Kettelhack C., Frerich B., Keilholz U., Dummer R., Sebastian G., Tilgen W., Schuler G., Mackensen A., Kaufmann R. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res. 2008, 18:152-160.
4. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Elashoff R., Essner R., Nieweg O.E., Roses D.F., Hoekstra H.J., Karakousis C.P., Reintgen D.S., Coventry B.J., Glass E.C., Wang H.J. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 2006, 355:1307-1317.
5. Shah J.P., Gil Z. Current concepts in management of oral cancer-surgery. Oral Oncol. 2009, 45:394-401.
6. Gil Z., Even-Sapir E., Margalit N., Fliss D.M. Integrated PET/CT system for staging and surveillance of skull base tumors. Head Neck 2007, 29:537-545.
7. Chang S.S., Amin M.B. Utilizing the tumor-node-metastasis staging for prostate cancer: the sixth edition, 2002. CA Cancer J. Clin. 2008, 58:54-59.
8. Vogl T., Bisdas S. Lymph node staging. Top. Magn. Reson. Imaging 2007, 18:303-316.
9. Schmidt G.P., Kramer H., Reiser M.F., Glaser C. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top. Magn. Reson. Imaging 2007, 18:193-202.
10. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., Maziere B. FDG accumulation and tumor biology. Nucl. Med. Biol. 1998, 25:317-322.
11. Zhuang H., Pourdehnad M., Lambright E.S., Yamamoto A.J., Lanuti M., Li P., Mozley P.D., Rossman M.D., Albelda S.M., Alavi A. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J. Nucl. Med. 2001, 42:1412-1417.
12. Bakheet S.M., Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin. Nucl. Med. 1998, 28:352-358.
13. Sugawara Y., Braun D.K., Kison P.V., Russo J.E., Zasadny K.R., Wahl R.L. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur. J. Nucl. Med. 1998, 25:1238-1243.
14. Zhuang H., Duarte P.S., Pourdehand M., Shnier D., Alavi A. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin. Nucl. Med. 2000, 25:281-284.
15. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur. J. Nucl. Med. 1996, 23:1409-1415.
16. Schoder H., Carlson D.L., Kraus D.H., Stambuk H.E., Gonen M., Erdi Y.E., Yeung H.W., Huvos A.G., Shah J.P., Larson S.M., Wong R.J. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J. Nucl. Med. 2006, 47:755-762.
17. Lim H.S., Yoon W., Chung T.W., Kim J.K., Park J.G., Kang H.K., Bom H.S., Yoon J.H. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007, 27(Suppl 1):S197-S213.
18. R.J. Hicks, Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy, Cancer Imaging, 10 Spec no A S83-91.
19. Brader P., Kelly K.J., Chen N., Yu Y.A., Zhang Q., Zanzonico P., Burnazi E.M., Ghani R.E., Serganova I., Hricak H., Szalay A.A., Fong Y., Blasberg R.G. Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene. Clin. Cancer Res. 2009, 15:3791-3801.
20. Likar Y., Dobrenkov K., Olszewska M., Vider E., Shenker L., Cai S., Pillarsetty N., Hricak H., Ponomarev V. A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs. J. Nucl. Med. 2008, 49:713-720.
21. Gil Z., Rein A., Brader P., Li S., Shah J.P., Fong Y., Wong R.J. Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin. Cancer Res. 2007, 13:6479-6485.
22. Kelly K., Brader P., Rein A., Shah J.P., Wong R.J., Fong Y., Gil Z. Attenuated multimutated herpes simplex virus∓1 effectively treats prostate carcinomas with neural invasion while preserving nerve function. FASEB J. 2008, 22:1839-1848.
23. De A., Lewis X.Z., Gambhir S.S. Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. Mol. Ther. 2003, 7:681-691.
24. Gambhir S.S., Barrio J.R., Wu L., Iyer M., Namavari M., Satyamurthy N., Bauer E., Parrish C., MacLaren D.C., Borghei A.R., Green L.A., Sharfstein S., Berk A.J., Cherry S.R., Phelps M.E., Herschman H.R. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J. Nucl. Med. 1998, 39:2003-2011.
25. Bennett J.J., Tjuvajev J., Johnson P., Doubrovin M., Akhurst T., Malholtra S., Hackman T., Balatoni J., Finn R., Larson S.M., Federoff H., Blasberg R., Fong Y. Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat. Med. 2001, 7:859-863.
26. Serganova I., Ponomarev V., Blasberg R. Human reporter genes: potential use in clinical studies. Nucl. Med. Biol. 2007, 34:791-807.
27. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
28. Soghomonyan S.A., Doubrovin M., Pike J., Luo X., Ittensohn M., Runyan J.D., Balatoni J., Finn R., Tjuvajev J.G., Blasberg R., Bermudes D. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 2005, 12:101-108.
29. Brader P., Stritzker J., Riedl C.C., Zanzonico P., Cai S., Burnazi E.M., Ghani E.R., Hricak H., Szalay A.A., Fong Y., Blasberg R. Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin. Cancer Res. 2008, 14:2295-2302.
30. Moore A.E. Effect of inoculation of the viruses of influenza A and herpes simplex on the growth of transplantable tumors in mice. Cancer 1949, 2:516-524.
31. Yu Z., Adusumilli P.S., Eisenberg D.P., Darr E., Ghossein R.A., Li S., Liu S., Singh B., Shah J.P., Fong Y., Wong R.J. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol. Ther. 2007, 15:103-113.
32. Gil Z., Kelly K.J., Brader P., Shah J.P., Fong Y., Wong R.J. Utility of a herpes oncolytic virus for the detection of neural invasion by cancer. Neoplasia 2008, 10:347-353.
33. Watanabe D., Goshima F., Mori I., Tamada Y., Matsumoto Y., Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J. Dermatol. Sci. 2008, 50:185-196.
34. McKee T.D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J.P., Bawendi M.G., Boucher Y., Breakefield X.O., Jain R.K. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006, 66:2509-2513.
35. Wong R.J., Chan M.K., Yu Z., Kim T.H., Bhargava A., Stiles B.M., Horsburgh B.C., Shah J.P., Ghossein R.A., Singh B., Fong Y. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 2004, 10:251-259.
36. Stiles B.M., Bhargava A., Adusumilli P.S., Stanziale S.F., Kim T.H., Rusch V.W., Fong Y. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003, 134:357-364.
37. Stiles B.M., Adusumilli P.S., Bhargava A., Stanziale S.F., Kim T.H., Chan M.K., Huq R., Wong R., Rusch V.W., Fong Y. Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther. 2006, 13:53-64.
38. Ramakrishnan R., Fink D.J., Jiang G., Desai P., Glorioso J.C., Levine M. Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J. Virol. 1994, 68:1864-1873.
39. Meignier B., Martin B., Whitley R.J., Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 1990, 162:313-321.
40. Kemeny N., Brown K., Covey A., Kim T., Bhargava A., Brody L., Guilfoyle B., Haag N.P., Karrasch M., Glasschroeder B., Knoll A., Getrajdman G., Kowal K.J., Jarnagin W.R., Fong Y. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum. Gene Ther. 2006, 17:1214-1224.
41. Johnson M., Huyn S., Burton J., Sato M., Wu L. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum. Gene Ther. 2006, 17:1262-1269.
42. Kishimoto H., Kojima T., Watanabe Y., Kagawa S., Fujiwara T., Uno F., Teraishi F., Kyo S., Mizuguchi H., Hashimoto Y., Urata Y., Tanaka N. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat. Med. 2006, 12:1213-1219.
43. Labow D., Lee S., Ginsberg R.J., Crystal R.G., Korst R.J. Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum. Gene Ther. 2000, 11:759-769.
44. Yu Z., Li S., Huang Y.Y., Lin S.F., Fong Y., Wong R.J. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy. Clin. Cancer Res. 2008, 14:1897-1904.
45. Varghese S., Rabkin S.D., Nielsen G.P., MacGarvey U., Liu R., Martuza R.L. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007, 67:9371-9379.
46. Adusumilli P.S., Stiles B.M., Chan M.K., Eisenberg D.P., Yu Z., Stanziale S.F., Huq R., Wong R.J., Rusch V.W., Fong Y. Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J. 2006, 20:726-728.
47. Wong R.J., Joe J.K., Kim S.H., Shah J.P., Horsburgh B., Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum. Gene Ther. 2002, 13:1213-1223.
48. Sprecher E., Becker Y. Langerhans cell density and activity in mouse skin and lymph nodes affect herpes simplex type 1 (HSV-1) pathogenicity. Arch. Virol. 1989, 107:191-205.
49. Eisenberg D.P., Adusumilli P.S., Hendershott K.J., Chung S., Yu Z., Chan M.K., Hezel M., Wong R.J., Fong Y. Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus. Ann. Surg. 2006, 243:824-830. (discussion 830-822).
50. Adusumilli P.S., Eisenberg D.P., Stiles B.M., Chung S., Chan M.K., Rusch V.W., Fong Y. Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus. J. Thorac. Cardiovasc. Surg. 2006, 132:1179-1188.
51. Tjuvajev J.G., Avril N., Oku T., Sasajima T., Miyagawa T., Joshi R., Safer M., Beattie B., DiResta G., Daghighian F., Augensen F., Koutcher J., Zweit J., Humm J., Larson S.M., Finn R., Blasberg R. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998, 58:4333-4341.
52. Tjuvajev J.G., Finn R., Watanabe K., Joshi R., Oku T., Kennedy J., Beattie B., Koutcher J., Larson S., Blasberg R.G. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res. 1996, 56:4087-4095.
53. Tjuvajev J.G., Stockhammer G., Desai R., Uehara H., Watanabe K., Gansbacher B., Blasberg R.G. Imaging the expression of transfected genes in vivo. Cancer Res. 1995, 55:6126-6132.
54. Soghomonyan S., Hajitou A., Rangel R., Trepel M., Pasqualini R., Arap W., Gelovani J.G., Alauddin M.M. Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU. Nat. Protoc. 2007, 2:416-423.
55. Alauddin M.M., Conti P.S. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl. Med. Biol. 1998, 25:175-180.
56. Yaghoubi S.S., Couto M.A., Chen C.C., Polavaram L., Cui G., Sen L., Gambhir S.S. Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression. J. Nucl. Med. 2006, 47:706-715.
57. Brust P., Haubner R., Friedrich A., Scheunemann M., Anton M., Koufaki O.N., Hauses M., Noll S., Noll B., Haberkorn U., Schackert G., Schackert H.K., Avril N., Johannsen B. Comparison of [18F]FHPG and [124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression. Eur. J. Nucl. Med. 2001, 28:721-729.
58. Alauddin M.M., Conti P.S., Mazza S.M., Hamzeh F.M., Lever J.R. 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET. Nucl. Med. Biol. 1996, 23:787-792.
59. Buursma A.R., Rutgers V., Hospers G.A., Mulder N.H., Vaalburg W., de Vries E.F. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nucl. Med. Commun. 2006, 27:25-30.
60. Serganova I., Doubrovin M., Vider J., Ponomarev V., Soghomonyan S., Beresten T., Ageyeva L., Serganov A., Cai S., Balatoni J., Blasberg R., Gelovani J. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res. 2004, 64:6101-6108.
61. Alauddin M.M., Shahinian A., Park R., Tohme M., Fissekis J.D., Conti P.S. In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:822-829.
62. Miyagawa T., Gogiberidze G., Serganova I., Cai S., Balatoni J.A., Thaler H.T., Ageyeva L., Pillarsetty N., Finn R.D., Blasberg R.G. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J. Nucl. Med. 2008, 49:637-648.
63. Chacko A.M., Blankemeyer E., Lieberman B.P., Qu W., Kung H.F. 5-[18F]Fluoroalkyl pyrimidine nucleosides: probes for positron emission tomography imaging of herpes simplex virus type 1 thymidine kinase gene expression. Nucl. Med. Biol. 2009, 36:29-38.
64. Brader P., Kelly K., Gang S., Shah J.P., Wong R.J., Hricak H., Blasberg R.G., Fong Y., Gil Z. Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One 2009, 4:e4789.
65. Gil Z., Carlson D.L., Gupta A., Lee N., Hoppe B., Shah J.P., Kraus D.H. Patterns and incidence of neural invasion in patients with cancers of the paranasal sinuses. Arch. Otolaryngol. Head Neck Surg. 2009, 135:173-179.
66. Gil Z., Cavel O., Kelly K., Brader P., Rein A., Gao S.P., Carlson D.L., Shah J.P., Fong Y., Wong R.J. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J. Natl. Cancer Inst. 2010, 102:107-118.
67. Burton J.B., Johnson M., Sato M., Koh S.B., Mulholland D.J., Stout D., Chatziioannou A.F., Phelps M.E., Wu H., Wu L. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat. Med. 2008, 14:882-888.
68. Wu L., Matherly J., Smallwood A., Adams J.Y., Billick E., Belldegrun A., Carey M. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 2001, 8:1416-1426.
69. Kelly K.J., Brader P., Woo Y., Li S., Chen N., Yu Y.A., Szalay A.A., Fong Y. Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model. Int. J. Cancer 2009, 124:911-918.
70. Serganova I., Moroz E., Vider J., Gogiberidze G., Moroz M., Pillarsetty N., Doubrovin M., Minn A., Thaler H.T., Massague J., Gelovani J., Blasberg R. Multimodality imaging of TGFbeta signaling in breast cancer metastases. FASEB J. 2009, 23:2662-2672.
71. Deng W.P., Wu C.C., Lee C.C., Yang W.K., Wang H.E., Liu R.S., Wei H.J., Gelovani J.G., Hwang J.J., Yang D.M., Fu Y.K., Wu C.W. Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. J. Nucl. Med. 2006, 47:877-884.
72. Ray P., De A., Min J.J., Tsien R.Y., Gambhir S.S. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res. 2004, 64:1323-1330.
73. Bhang H.E., Gabrielson K.L., Laterra J., Fisher P.B., Pomper M.G. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat. Med. 2011, 17:123-129.
74. Su Z.Z., Sarkar D., Emdad L., Duigou G.J., Young C.S., Ware J., Randolph A., Valerie K., Fisher P.B. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1059-1064.
75. Su Z., Shi Y., Fisher P.B. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 2000, 19:3411-3421.
76. Jacobs A., Voges J., Reszka R., Lercher M., Gossmann A., Kracht L., Kaestle C., Wagner R., Wienhard K., Heiss W.D. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001, 358:727-729.
77. Penuelas I., Mazzolini G., Boan J.F., Sangro B., Marti-Climent J., Ruiz M., Ruiz J., Satyamurthy N., Qian C., Barrio J.R., Phelps M.E., Richter J.A., Gambhir S.S., Prieto J. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005, 128:1787-1795.
78. Hecht J.R., Bedford R., Abbruzzese J.L., Lahoti S., Reid T.R., Soetikno R.M., Kirn D.H., Freeman S.M. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 2003, 9:555-561.
79. Jacobs A., Braunlich I., Graf R., Lercher M., Sakaki T., Voges J., Hesselmann V., Brandau W., Wienhard K., Heiss W.D. Quantitative kinetics of [124I]FIAU in cat and man. J. Nucl. Med. 2001, 42:467-475.
80. Diaz L.A., Foss C.A., Thornton K., Nimmagadda S., Endres C.J., Uzuner O., Seyler T.M., Ulrich S.D., Conway J., Bettegowda C., Agrawal N., Cheong I., Zhang X., Ladenson P.W., Vogelstein B.N., Mont M.A., Zhou S., Kinzler K.W., Vogelstein B., Pomper M.G. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One 2007, 2:e1007.
81. A. Ruggiero, P. Brader, I. Serganova, P. Zanzonico, S. Cai, N.S. Lipman, H. Hricak, R.G. Blasberg, Different strategies for reducing intestinal background radioactivity associated with imaging HSV1-tk expression using established radionucleoside probes, Mol. Imaging 9 (2010) 47-58.
82. Kuruppu D., Brownell A.L., Zhu A., Yu M., Wang X., Kulu Y., Fuchs B.C., Kawasaki H., Tanabe K.K. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res. 2007, 67:3295-3300.